Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) has announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 18,000 common shares at $0.80 each. This purchase increased Cerrone’s beneficial ownership from 37.58% to 37.60% of the company. Tiziana is focused on developing innovative immunotherapies using alternative drug delivery methods, including intranasal and inhalation approaches, with its lead candidates showing favorable safety profiles and clinical responses.

Positive

• The acquisition by Panetta Partners Limited indicates continued confidence in the company's prospects.
• Tiziana's innovative drug delivery technologies may improve efficacy and safety over traditional methods.

Negative

• None.

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, purchased 18,000 common shares at $0.80 per share.

The acquisition takes Mr Cerrone's interests from 37.58% to 37.60%.

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

Tiziana Life Sciences Ltd

Hana Malik, Business Development,
and Investor Relations Manager  
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com

FAQ

What is the recent share acquisition by Gabriele Cerrone related to TLSA?

Panetta Partners Limited purchased 18,000 common shares at $0.80, increasing Cerrone's ownership from 37.58% to 37.60%.

What are Tiziana Life Sciences' key areas of focus?

Tiziana specializes in developing immunotherapies using alternative drug delivery methods such as nasal and inhalation routes.

What are the lead candidates of Tiziana Life Sciences?

The lead candidates include intranasal foralumab, a fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor.

How does Tiziana's drug delivery technology compare to traditional methods?

Tiziana's technologies aim to improve therapeutic efficacy and safety compared to intravenous delivery.